Successful Treatment of 3 Dogs With Fluoroquinolone-Resistant Escherichia coli Associated Granulomatous Colitis

Top Companion Anim Med. 2022 Mar-Apr:47:100621. doi: 10.1016/j.tcam.2021.100621. Epub 2021 Dec 26.

Abstract

Successful resolution of Escherichia coli associated granulomatous colitis (ECGC) is becoming a challenge due to the development of fluoroquinolone resistant E coli, which is associated with poor prognosis. Three dogs presented with signs of chronic colitis and were diagnosed with ECGC. All 3 were initially treated with enrofloxacin and trimethoprim-sulfamethoxazole, without clinical improvement. Despite the fact that culture and susceptibility testing results demonstrate resistance to fluoroquinolone and trimethoprim-sulfamethoxazole, the addition of amikacin fully resolved the clinical signs in all 3 cases. This case series describes the clinical presentation, diagnostic findings, and successful treatment of 3 dogs with fluoroquinolone-resistant ECGC. It suggests an alternative strategy for multidrug-resistance ECGC patients. Further investigations are required to confirm the efficacy of and to determine the molecular mechanisms underpinning the apparent success of aminoglycoside antibiotic combinations for treatment of ECGC.

Keywords: Antibiotics; amikacin; aminoglycosides; diarrhea; fluoroquinolone; resistance.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Crohn Disease* / drug therapy
  • Crohn Disease* / veterinary
  • Dog Diseases* / drug therapy
  • Dogs
  • Escherichia coli
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / veterinary
  • Fluoroquinolones / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones